S3 celecoxib: expanding pharmacists’ options for managing musculoskeletal pain

The recent decision by the Therapeutic Goods Administration to include celecoxib 200mg as the first Schedule 3 (Pharmacist Only Medicine) selective COX-2 inhibitor in a primary pack containing not more than 10 dosage units for the short-term treatment of acute pain due to primary dysmenorrhoea or musculoskeletal or soft tissue injury in adults provides pharmacists